Doddy Irawan Setyo Utomo

Dr. Doddy Irawan Setyo Utomo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
DUDoddy Irawan Setyo Utomo
Doddy Irawan Setyo Utomo
HSHamizah Suhaimi
Hamizah Suhaimi
NANor Azila Muhammad Azami
Nor Azila Muhammad Azami
FAFazren Azmi
Fazren Azmi
MAMohd Cairul Iqbal Mohd Amin
Mohd Cairul Iqbal Mohd Amin
Jian XuJian Xu
Jian Xu
Recently, a great effort has been devoted to studying attenuated and subunit vaccine development against SARS-CoV-2 since its outbreak in December 2019. It is known that diverse virus-like particles (VLPs) are extensively employed as carriers to display various antigenic and immunostimulatory cargo modules for vaccine development. Single or multiple antigens or antigenic domains such as the spike or nucleocapsid protein or their variants from SARS-CoV-2 could also be incorporated into VLPs via either a genetic or chemical display approach. Such antigen display platforms would help screen safer and more effective vaccine candidates capable of generating a strong immune response with or without adjuvant. This review aims to provide valuable insights for the future development of SARS-CoV-2 VLP vaccines by summarizing the latest updates and perspectives on the vaccine development of VLP platforms for genetic and chemical displaying antigens from SARS-CoV-2.


1 January 2026 in Journal of Veterinary Science
Verified
Journal Article
Open access
PDF file
DUDoddy Irawan Setyo Utomo
Doddy Irawan Setyo Utomo
NDnlp Indi Dharmayanti
nlp Indi Dharmayanti
Masteria Yunovilsa PutraMasteria Yunovilsa Putra
Masteria Yunovilsa Putra
Utomo DI, et al. J Vet Sci. 2026 Jan;27:e16. https://doi.org/10.4142/jvs.25160

30 August 2026 in AMB Express
Verified
Journal Article
Open access
PDF file
DUDoddy Irawan Setyo Utomo
Doddy Irawan Setyo Utomo
ABAsep Bayu
Asep Bayu
MRMuhammad Luqman Ar Rasyid
Muhammad Luqman Ar Rasyid
ANAstutiati Nurhasanah
Astutiati Nurhasanah
SRSiti Irma Rahmawati
Siti Irma Rahmawati
Masteria Yunovilsa PutraMasteria Yunovilsa Putra
Masteria Yunovilsa Putra
The dengue virus (DENV) remains a significant global health threat, and the currently available vaccines exhibit concerns regarding safety, efficacy, and cost-effectiveness. Microalgae represent an innovative method for producing proteins that do not occur naturally. They are Generally Recognized As Safe (GRAS), easily scalable, and capable of inducing post-translational modifications in eukaryotes. This study illustrates the effective heterologous expression of recombinant dengue virus capsid–premembrane–envelope (C-prM-E) structural antigen constructs representing all four DENV serotypes (DV1–DV4) in the red microalga Porphyridium purpureum through Agrobacterium tumefaciens -mediated transformation. Gene constructs containing capsid-premembrane-envelope (CprME) polyprotein fragments with C-terminal epitope tags were cloned into pCAMBIA1301 vectors and subsequently introduced into P. purpureum . PCR amplification confirmed the successful chromosomal integration of all four serotype constructs, yielding the anticipated 2.5-kb amplicons. The SDS-PAGE analysis revealed protein bands at around 85 kDa, consistent with the expected molecular weight of the processed CprME-derived proteins. We employed both anti-DENV-2 and anti-FLAG antibodies in a western blot assay to demonstrate that the recombinant antigens were identical and interacted with the immune system across all serotypes. These findings indicate that P. purpureum is an effective system for expressing DENV antigens, paving the path for the development of cost-effective, plant-derived dengue vaccine candidates. This microalgal platform may facilitate the large-scale production of tetravalent dengue vaccines, particularly in regions where dengue is prevalent and resources are scarce.